Cargando…

Limited Marginal Utility of Deep Sequencing for HIV Drug Resistance Testing in the Age of Integrase Inhibitors

HIV drug resistance genotyping is a critical tool in the clinical management of HIV infections. Although resistance genotyping has traditionally been conducted using Sanger sequencing, next-generation sequencing (NGS) is emerging as a powerful tool due to its ability to detect low-frequency alleles....

Descripción completa

Detalles Bibliográficos
Autores principales: Dalmat, Ronit R., Makhsous, Negar, Pepper, Gregory G., Magaret, Amalia, Jerome, Keith R., Wald, Anna, Greninger, Alexander L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258839/
https://www.ncbi.nlm.nih.gov/pubmed/30305383
http://dx.doi.org/10.1128/JCM.01443-18
_version_ 1783374569305800704
author Dalmat, Ronit R.
Makhsous, Negar
Pepper, Gregory G.
Magaret, Amalia
Jerome, Keith R.
Wald, Anna
Greninger, Alexander L.
author_facet Dalmat, Ronit R.
Makhsous, Negar
Pepper, Gregory G.
Magaret, Amalia
Jerome, Keith R.
Wald, Anna
Greninger, Alexander L.
author_sort Dalmat, Ronit R.
collection PubMed
description HIV drug resistance genotyping is a critical tool in the clinical management of HIV infections. Although resistance genotyping has traditionally been conducted using Sanger sequencing, next-generation sequencing (NGS) is emerging as a powerful tool due to its ability to detect low-frequency alleles. However, the clinical value added from NGS approaches to antiviral resistance testing remains to be demonstrated. We compared the variant detection capacity of NGS versus Sanger sequencing methods for resistance genotyping in 144 drug resistance tests (105 protease-reverse transcriptase tests and 39 integrase tests) submitted to our clinical virology laboratory over a four-month period in 2016 for Sanger-based HIV drug resistance testing. NGS detected all true high-frequency drug resistance mutations (>20% frequency) found by Sanger sequencing, with greater accuracy in one instance of a Sanger-detected false positive. Freely available online NGS variant callers HyDRA and PASeq were superior to Sanger methods for interpretations of allele linkage and automated variant calling. NGS additionally detected low-frequency mutations (1 to 20% frequency) associated with higher levels of drug resistance in 30/105 (29%) protease-reverse transcriptase tests and 4/39 (10%) integrase tests. In clinical follow-up of 69 individuals for a median of 674 days, we did not find a difference in rates of virological failure between individuals with and without low-frequency mutations, although rates of virological failure were higher for individuals with drug-relevant low-frequency mutations. However, all 27 individuals who experienced virological failure reported poor adherence to their drug regimen during the preceding follow-up time, and all 19 who subsequently improved their adherence achieved viral suppression at later time points, consistent with a lack of clinical resistance. In conclusion, in a population with low antiviral resistance emergence, NGS methods detected numerous instances of minor alleles that did not result in subsequent bona fide virological failure due to antiviral resistance.
format Online
Article
Text
id pubmed-6258839
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-62588392018-12-13 Limited Marginal Utility of Deep Sequencing for HIV Drug Resistance Testing in the Age of Integrase Inhibitors Dalmat, Ronit R. Makhsous, Negar Pepper, Gregory G. Magaret, Amalia Jerome, Keith R. Wald, Anna Greninger, Alexander L. J Clin Microbiol Virology HIV drug resistance genotyping is a critical tool in the clinical management of HIV infections. Although resistance genotyping has traditionally been conducted using Sanger sequencing, next-generation sequencing (NGS) is emerging as a powerful tool due to its ability to detect low-frequency alleles. However, the clinical value added from NGS approaches to antiviral resistance testing remains to be demonstrated. We compared the variant detection capacity of NGS versus Sanger sequencing methods for resistance genotyping in 144 drug resistance tests (105 protease-reverse transcriptase tests and 39 integrase tests) submitted to our clinical virology laboratory over a four-month period in 2016 for Sanger-based HIV drug resistance testing. NGS detected all true high-frequency drug resistance mutations (>20% frequency) found by Sanger sequencing, with greater accuracy in one instance of a Sanger-detected false positive. Freely available online NGS variant callers HyDRA and PASeq were superior to Sanger methods for interpretations of allele linkage and automated variant calling. NGS additionally detected low-frequency mutations (1 to 20% frequency) associated with higher levels of drug resistance in 30/105 (29%) protease-reverse transcriptase tests and 4/39 (10%) integrase tests. In clinical follow-up of 69 individuals for a median of 674 days, we did not find a difference in rates of virological failure between individuals with and without low-frequency mutations, although rates of virological failure were higher for individuals with drug-relevant low-frequency mutations. However, all 27 individuals who experienced virological failure reported poor adherence to their drug regimen during the preceding follow-up time, and all 19 who subsequently improved their adherence achieved viral suppression at later time points, consistent with a lack of clinical resistance. In conclusion, in a population with low antiviral resistance emergence, NGS methods detected numerous instances of minor alleles that did not result in subsequent bona fide virological failure due to antiviral resistance. American Society for Microbiology 2018-11-27 /pmc/articles/PMC6258839/ /pubmed/30305383 http://dx.doi.org/10.1128/JCM.01443-18 Text en Copyright © 2018 Dalmat et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Virology
Dalmat, Ronit R.
Makhsous, Negar
Pepper, Gregory G.
Magaret, Amalia
Jerome, Keith R.
Wald, Anna
Greninger, Alexander L.
Limited Marginal Utility of Deep Sequencing for HIV Drug Resistance Testing in the Age of Integrase Inhibitors
title Limited Marginal Utility of Deep Sequencing for HIV Drug Resistance Testing in the Age of Integrase Inhibitors
title_full Limited Marginal Utility of Deep Sequencing for HIV Drug Resistance Testing in the Age of Integrase Inhibitors
title_fullStr Limited Marginal Utility of Deep Sequencing for HIV Drug Resistance Testing in the Age of Integrase Inhibitors
title_full_unstemmed Limited Marginal Utility of Deep Sequencing for HIV Drug Resistance Testing in the Age of Integrase Inhibitors
title_short Limited Marginal Utility of Deep Sequencing for HIV Drug Resistance Testing in the Age of Integrase Inhibitors
title_sort limited marginal utility of deep sequencing for hiv drug resistance testing in the age of integrase inhibitors
topic Virology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258839/
https://www.ncbi.nlm.nih.gov/pubmed/30305383
http://dx.doi.org/10.1128/JCM.01443-18
work_keys_str_mv AT dalmatronitr limitedmarginalutilityofdeepsequencingforhivdrugresistancetestingintheageofintegraseinhibitors
AT makhsousnegar limitedmarginalutilityofdeepsequencingforhivdrugresistancetestingintheageofintegraseinhibitors
AT peppergregoryg limitedmarginalutilityofdeepsequencingforhivdrugresistancetestingintheageofintegraseinhibitors
AT magaretamalia limitedmarginalutilityofdeepsequencingforhivdrugresistancetestingintheageofintegraseinhibitors
AT jeromekeithr limitedmarginalutilityofdeepsequencingforhivdrugresistancetestingintheageofintegraseinhibitors
AT waldanna limitedmarginalutilityofdeepsequencingforhivdrugresistancetestingintheageofintegraseinhibitors
AT greningeralexanderl limitedmarginalutilityofdeepsequencingforhivdrugresistancetestingintheageofintegraseinhibitors